Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Betta Pharma Signs $135 Million Deal for China Rights to Two Immunotherapies

publication date: Jun 22, 2020

Hangzhou Betta Pharma signed a $135 million deal to in-license China rights for two immunotherapies from Agenus of Massachusetts. The two candidates are balstilimab, an anti-PD-1, expected to file for US approval this year, and zalifrelima, an anti-CTLA-4. They are being tested to treat refractory or metastatic cervical cancer. Betta will pay $35 million upfront ($15 million in cash and a $20 million equity investment) plus $100 million in potential milestones, and it will make royalty payments on net sales. More details....

Stock Symbols: (SHZ: 300558) (NSDQ: AGEN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here